Chronic myelomonocytic leukemia patients with RAS pathway mutations show high in vitro myeloid colony formation in the absence of exogenous growth factors.

We read with great interest the article by Akutagawa et al.[1] in this journal in which the authors describe that PI3K inhibitors unexpectedly profoundly inhibited myeloproliferation in an myelodysplastic/myeloproliferative neoplasm mouse model driven by hyperactive RAS, suggesting a new therapeutic strategy in juvenile myelomonocytic leukemia (JMML) and chronic myelomonocytic leukemia (CMML).

The basis for all RAS pathway-oriented treatment concepts is the identification of RAS pathway hyperactivation in patients. Due to the fact that in CMML more than one molecular aberration can be detected in the majority of patients, functional tests may be important to better estimate the contribution of a particular molecular aberration in the pathogenesis of the malignancy.[2] In JMML, in which molecular aberrations are mainly restricted to the RASopathy genes, including NRAS, KRAS, NF1, CBL and PTPN11, the spontaneous formation of colony-forming unit-granulocyte-macrophage (CFU-GM) due to granulocyte/macrophage colony-stimulating factor (GM-CSF)-specific hypersensitivity is a hallmark feature of disease, which has been included in the diagnostic criteria.[3]

We have originally reported that extensive in vitro formation of CFU-GM without exogenous growth factors can also be found in a subset of patients with CMML.[4] We demonstrated that this spontaneous myeloid colony formation in CMML is a GM-CSF-dependent in vitro phenomenon and could also show that CMML patients with high spontaneous CFU-GM growth (>100/105 PBMNC) have a worse prognosis compared with patients with low CFU-GM growth, suggesting a clinical significance of our observation.[5, 6]

We speculated that spontaneous myeloid colony formation might be a surrogate parameter of RAS pathway hyperactivation in CMML. To test this hypothesis, we performed next-generation sequencing (NGS) from stored peripheral blood mononuclear cells (PB MNC) obtained from 100 CMML patients, in whom in vitro cultures have been performed during the last years. In vitro culture data were then correlated with molecular aberrations of RAS pathway components.

The diagnosis of CMML was made according to the diagnostic criteria of the World Health Organization classification of 2008.[7] For molecular characterization, we used NGS with amplicon-based target enrichment of 39 CMML-associated genes, including ASXL1, EGFR, KRAS, SF3A1, ATRX, ETV6, MET, SF3B1, BCOR, EZH2, NF1, SRSF2, BRAF, FLT3, NPM1, STAG2, CBL, GNAS, NRAS, TET2, CDKN2A, IDH1, PRPF40B, TP53, CEBPA, IDH2, PTPN11, U2AF1, CSF1R, JAK2, RUNX1, WT1, CSF3R, KDM6A, SETBP1, ZRSR2, DNMT3A, KIT and SF1. Assuming that clones that are too small are unlikely to significantly impact hematopoiesis, only mutations with an allele burden of 20% or higher were considered as positive for analysis. CFU-GM growth in the absence of exogenous cytokines was assessed using semisolid cultures as previously described.[5]

In 40 CMML patients, mutations in at least one of the RASopathy genes were detected; in 60 patients, no mutations in RAS pathway components or such mutations with allele frequencies <20% were found. In the 40 patients with RAS pathway mutations, we found molecular aberrations of the NRAS gene in 19, KRAS in 6, NF1 in 3, CBL in 10 and PTPN11 in 2 patients, respectively. Mutations of RAS pathway components were mutually exclusive, only low levels of more than one RASopathy mutations were found in some patients. In all patients with RAS pathway mutations, additional mutations were observed in other genes, particularly in components of DNA methylation and/or the spliceosome as previously reported by others.[2] Results of semisolid cultures show that in CMML patients in whom molecular aberration in RAS pathway components could be detected had a much higher spontaneous myeloid colony formation than CMML patients without RAS pathway mutations (Figure 1). The median number of spontaneously formed CFU-GM/105 MNC was 147.5 (range 0–1009) in RAS-positive patients as compared with 2 (0–812) in RAS-negative patients (P<0.00001 by the Wilcoxon's rank-sum test). Unstimulated myeloid colony formation in RAS-positive CMML patients is also much higher than the spontaneous formation of CFU-GM in normal individuals (median 4.8/105 PBMNC, range 3.5–8.5), which has been reported by us previously.[8] The incidence of RAS pathway mutations was 72% (21/29) in CMML patients with high-colony growth (>100/105 PBMNC) and 27% (19/71) in patients with low spontaneous CFU-GM formation (P<0.0001 by the chi square test). In eight patients, high CFU-GM growth was observed without evidence of genetic aberrations in RAS signaling. This may indicate that additional molecular aberrations of the RAS pathway, which are not covered by our targeted NGS panel, may cause spontaneous cell proliferation, or, alternatively, that other signaling pathways may also play a certain role in this in vitro phenomenon.

Figure 1

Comparison of spontaneous in vitro CFU-GM growth from PBMNC in CMML patients with and without mutations in RASopathy genes, including NRAS, KRAS, NF1, CBL and PTPN11. CFU-GM formation in the absence of exogenous cytokines was assessed using semisolid cultures as previously described.[5] Colony numbers are shown as box plots with first and third quartiles and interquartile ranges. Data were analyzed using the Wilcoxon's rank-sum test. Spontaneous myeloid colony formation was significantly higher in CMML patients with mutations in RAS pathway components than in patients without such mutations (P<0.00001).

Our findings suggest that high spontaneous myeloid colony growth in CMML is significantly associated with molecular aberrations of genes involved in RAS signaling and thus seems to reflect RAS pathway hyperactivation in patients with CMML. Therefore, spontaneous colony formation in semisolid cultures could be a helpful functional test to identify patients who are potential candidates for treatment concepts designed for patients with RAS pathway-driven hematologic malignancies.